Shopping Cart
- Remove All
- Your shopping cart is currently empty
Zymosan A, derived from Saccharomyces cerevisiae, is a TLR2 agonist and exhibits significant radioprotective effects, mitigating and preventing IR-induced intestinal injury in mice. Furthermore, Zymosan A aids in the regeneration of intestinal stem cells (ISCs) following IR injury [1].
Description | Zymosan A, derived from Saccharomyces cerevisiae, is a TLR2 agonist and exhibits significant radioprotective effects, mitigating and preventing IR-induced intestinal injury in mice. Furthermore, Zymosan A aids in the regeneration of intestinal stem cells (ISCs) following IR injury [1]. |
In vivo | Zymosan A is utilized in animal modeling to establish a mouse model of peritonitis. Administered at a dose of 25.0 mg/kg through intraperitoneal injection 12 hours and 2 hours before ischemia-reperfusion (IR) stress, Zymosan A mitigates IR-induced intestinal damage in mice [1]. |
Alias | Zymosan A from Saccharomyces cerevisiae |
Cas No. | 58856-93-2 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.